Preimplantation Genetic Diagnosis Market Synopsis:<\/p>\n
Preimplantation Genetic Diagnosis Market Size Was Valued at USD 57.3 Million in 2023, and is Projected to Reach USD 113.6 Million by 2032, Growing at a CAGR of 7.9% From 2024-2032.<\/p>\n
The Preimplantation Genetic Diagnosis (PGD) Market is the segment which deals with the diagnosis of genetic diseases or congenital abnormalities of the embryo during IVF treatment. PGD is employed to diagnose certain genetic disorders such as cystic fibrosis, sickle cell anemia and certain chromosomal disorders which allows couples to have healthy embryos be implanted into the wives womb. The public has embraced use of this technology because it can lower incidence of genetic diseases and enhance IVF outcomes therefore is widely used in fertility clinic the world over.<\/p>\n
The main factors responsible for market growth of PGD are the growth of the awareness concerning the genetic disorders, the raise of the infertility rate, tendencies in the development of the reproductive technologies.. PGD is believed to receive increased adoption as the techniques of IVF progress and as genetic testing becomes standard. Moreover, the modern trend of therapeutic genius is the individual approach for treatment according to the genetic test, which will also improve the demand for genetic testing in reproductive medicine. In addition, government measures and insurance coverage continuation in some areas also contribute to the market\u2019s growth.\u2022 However, there are issues that relate to the market for the delivery of CBD oil including; high costs, ethical issues, and regulation.s in reproductive technologies. As IVF techniques improve and the availability of genetic screening becomes more widespread, PGD is expected to see broader adoption. Additionally, the growing trend of personalized medicine, where treatments are tailored to individual genetic profiles, is likely to enhance the demand for genetic testing in reproductive healthcare. Furthermore, government initiatives and insurance coverage expansion in some regions also support the market’s growth.<\/p>\n
Despite the promising opportunities, the market faces challenges such as high costs, ethical concerns, and regulatory hurdles. Nevertheless, PGD procedures may be relatively costly and thus preclude widesprea adoption among the population. In the same regard, there are continuing ethical issues concerning the so-called social PGD, for instance, the use of PGD to determine the sex of the child. But progress in the field of genetics, enhancement of various social and technical factors to analyze the PGD, and growing need for fertility solutions make the market more favorable in the future years.<\/p>\n
Preimplantation Genetic Diagnosis Market Trend Analysis:<\/p>\n
Advancements in Genetic Testing Technologies<\/p>\n
The advances in the Preimplantation Genetic Diagnosis (PGD) market show that there is a progressive improvement of genetic testing technologies.. With the use of NGS, and other latest methods such as single-cell analysis, the efficiency of PGD has been tremendously boosted in terms of accuracy. These helped enable earlier identification of a larger number of genetic diseases and chromosomal abnormalities, greatly increasing the likelihood of pregnancy and the development of healthy embryos. With advancements in these technologies, these technologies are predicted to increase the use of PGD in fertility centers which in turn will help the market to grow attracting international investors.<\/p>\n
Rising Demand for Personalized Fertility Treatments<\/p>\n
The fourth trend that has been observed in the market of PGD is as follows:. The increasing number of people and couples in search of individual approaches to infertility treatment means that PGD acts as an important means for the successful implementation of IVF. Genetic therapies that are unique to the individual patient care are now more common with concerns arising from hereditary disease and other disorders on the rise. This trend is helping in promotion of PGD market because more individuals are using genetic screening as they prepare for family planning to minimize possibilities of passing on genetic disorders.<\/p>\n
Preimplantation Genetic Diagnosis Market Segment Analysis:<\/p>\n
Preimplantation Genetic Diagnosis Market is Segmented on the basis of Type, End User, and Region.<\/p>\n
By Type, Chromosomal Abnormalities segment is expected to dominate the market during the forecast period<\/p>\n
The Preimplantation Genetic Diagnosis (PGD) Market can be classified according to the tested kind of genetic problems which are capable of being diagnosed during the IVF process.These are chromosomal disorders including; down syndrome, aneuploidy which is involving an odd number of chromosomes, and X-linked diseases which affects individuals in line with their X chromosome. Furthermore, PGD is done to identify diseases related to single genes such as cystic fibrosis or sickle cell anemia, and HLA typing in order to bring together an embryo and a suitable stem cell to treat the child for some disease. Another area where PGD is employed is in sex selection , however , it draws a lot controversy regarding its functionality. Other testing done under PGD includes inheritance disease testing and other disease and conditions not categorized above making it encompass a wide realm in the field of reproductive medicine.<\/p>\n
By End User, Diagnostic Laboratories segment expected to held the largest share<\/p>\n
Based on end user the Preimplantation Genetic Diagnosis (PGD) market is divided into diagnostic laboratories, hospitals\/ clinics, and others.. The market share of diagnostic laboratories is also high because of the higher genetic testing technology and PGD equipment which are required for performing PGD processes. Primary care also contributes, particularly acute care hospitals proposing sophisticated infertility care with IVF, where PGD is an element of assistance. Fertility clinics are also a leading consumer because most of them run tests and treatment procedures that require PGD on behalf of their patients. Also, other market players including research institutions and private healthcare providers drive the market with focused solutions in genetic screening and adequate reproductive health. The shifting trend of precision medicine and genetic counseling in all such end-user segments is expected to facilitate increased usage of PGD.<\/p>\n
Preimplantation Genetic Diagnosis Market Regional Insights: <\/p>\n
North America is Expected to Dominate the Market Over the Forecast period <\/p>\n
North America region held the largest share in the Preimplantation Genetic Diagnosis (PGD) market during the forecast period, due to having the strong healthcare structure, higher market penetration of advanced Reproductive Technologies and genetics research investment.. The United States specifically takes a rather significant portion considering that a vast number of fertility clinics offering IVF services now include PGD as part of their package through strong insurance policies and governmental encouragement. Also there is increasing concern with genetic disorder and the need for specialized fertility treatments that targeting the areas region thus boosting the regions dominance. Another factor that continues to drive technological enhancements in the PGD market is North America where fertility clinics are expected to further consolidate their leadership during the forecast period.<\/p>\n
Active Key Players in the Preimplantation Genetic Diagnosis Market:<\/p>\n
PerkinElmer, Inc. (United States), <\/p>\n
Genea Limited (Australia),<\/p>\n
Thermo Fisher Scientific Inc. (United States), <\/p>\n
Agilent Technologies, Inc. (United States), <\/p>\n
Quest Diagnostics Incorporated (United States), <\/p>\n
Illumina, Inc. (United States),<\/p>\n
CooperSurgical, Inc. (United States), <\/p>\n
Beijing Genomics Institute (BGI) (China), <\/p>\n
LabCorp of America Holdings (Laboratory Corporation of America) (United States), <\/p>\n
Natera, Inc. (United States), <\/p>\n
Oxford Gene Technology (United Kingdom), <\/p>\n
California Pacific Medical Center (United States), <\/p>\n
Good Start Genetics, Inc. (United States), <\/p>\n
Invitae Corporation (United States), <\/p>\n
F. Hoffmann-La Roche AG (Switzerland), <\/p>\n
Progenesis (United Kingdom)<\/p>\n
Other Active Players<\/p>\n","protected":false},"excerpt":{"rendered":"
The Preimplantation Genetic Diagnosis (PGD) Market is the segment which deals with the diagnosis of genetic diseases or congenital abnormalities of the embryo during IVF treatment. PGD is employed to diagnose certain genetic disorders such as cystic fibrosis, sickle cell anemia and certain chromosomal disorders which allows couples to have healthy embryos be implanted into the wives womb.<\/p>\n","protected":false},"featured_media":7336,"template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[194],"product_tag":[],"class_list":["post-10132","product","type-product","status-publish","has-post-thumbnail","product_cat-healthcare-life-sciences","first","instock","virtual","purchasable","product-type-simple"],"acf":[],"yoast_head":"\n